Physician profile
Joseph Diaz
NPI 1417948241
$1,131,990.93
in general payments reported to CMS, 2019-2025
43 companies · $186K in 2025
The $186K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $31K · 2021: $153K · 2022: $226K · 2023: $212K · 2024: $174K · 2025: $186K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $451K · Travel and Lodging: $57K · Consulting Fee: $37K · Food and Beverage: $23K · Honoraria: $3,647 · Education: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $451,180.66 |
| Travel and Lodging | $56,633.48 |
| Consulting Fee | $36,560.25 |
| Food and Beverage | $23,125.99 |
| Honoraria | $3,647.00 |
| Education | $591.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $741,172.45 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genentech USA, INC. | $123,058.76 | 2019-2025 | Xolair |
| Amgen INC. | $69,219.76 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $56,413.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38,469.77 | 2020-2025 | Cinryze, Takhzyro, Cuvitru |
| Shire North American Group INC | $26,747.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15,841.23 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $14,642.84 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $10,617.45 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Csl Behring | $8,346.52 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Biocryst Pharmaceuticals, INC. | $7,428.52 | 2019-2025 | Orladeyo |
| Pfizer INC. | $5,217.81 | 2019-2023 | |
| Genzyme Corporation | $4,080.71 | 2019-2025 | |
| Blueprint Medicines Corporation | $4,063.53 | 2022-2024 | Ayvakit |
| Astrazeneca Uk Limited | $1,464.75 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,048.69 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $590.71 | 2020-2024 | |
| Pharming Healthcare, INC. | $565.38 | 2019-2024 | Joenja, Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.48 | 2020-2023 | Spiriva Respimat |
| Sunovion Pharmaceuticals INC. | $280.77 | 2019-2020 | |
| Alk-Abello, INC | $241.84 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Octapharma USA, INC. | $241.75 | 2021-2024 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Kaleo, INC. | $230.92 | 2019-2022 | |
| Optinose US, INC. | $211.04 | 2019-2023 | |
| Abbvie INC. | $190.01 | 2022-2024 | Rinvoq |
| Aimmune Therapeutics, INC. | $182.03 | 2020-2021 | |
| Grifols USA, LLC | $181.75 | 2019-2024 | Xembify, Gamunex-C |
| Mylan Specialty L.P. | $168.91 | 2019-2024 | Yupelri |
| Bio Products Laboratory USA, INC. | $125.94 | 2021-2023 | Gammaplex, Coagadex |
| Ars Pharmaceuticals Operations, INC. | $112.13 | 2025 | Neffy |
| Incyte Corporation | $109.71 | 2022-2024 | Opzelura |
| Adma Biomanufacturing LLC | $97.17 | 2025 | |
| Jubilant Hollisterstier LLC | $96.68 | 2019 | |
| Merck Sharp & Dohme LLC | $60.12 | 2021-2023 | |
| Genentech, INC. | $50.69 | 2023-2024 | Xolair |
| Olympus America INC. | $23.82 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.77 | 2025 | Alvesco |
| Circassia INC. | $18.15 | 2019 | |
| Hikma Pharmaceuticals USA | $13.23 | 2023 | Ryaltris |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$190,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.